Ivan Dikic

Ivan Dikic is Professor of biochemistry and director of Institute for biochemistry 2 at Goethe University and a Fellow of Max Planck Institute for Biophysics in Frankfurt. He is an international leader in the fields of ubiquitin biology and autophagy and explores pathological alterations in these pathways related to human disease development e.g. cancer, infection diseases and neurodegeneration.

His recent interests focus on proximity-inducing drugs including PROTACs and molecular glues, where he leads a large cluster consortium PROXIDRUGS. He was a co-founder of two biotech companies: Caraway Therapeutics in Boston USA (acquired by Merck in 2023) and Vivlion Biotech GmBH in Germany.

Ivan Dikic is an elected member of the EMBO, the German National Academy of Sciences Leopoldina and the American Academy of Arts and Sciences. For his scientific work he received multiple awards including the last year Louise-Jeantet Prize in medicine (2023), the Hans Krebs Award, the Jung Prize and the Leibniz Prize. Ivan Dikic is committed to education of the next generations of young scientists globally and spends significant time and energy in science popularisation.